Apellis Pharma is a global biopharmaceutical company that is dedicated to developing life-changing therapies for patients facing challenging diseases. Their innovative approach involves targeting C3, a part of the immune system known as the complement cascade, to treat diseases driven by excessive activation. Their therapeutic focus extends to areas including hematology, ophthalmology, and nephrology.

Apellis has made significant advancements in science by introducing the first new class of complement medicine in 15 years. They have successfully developed two approved medicines targeting C3, including the world's first therapy for geographic atrophy, a leading cause of blindness. With multiple clinical and pre-clinical programs underway, Apellis is continuously uncovering the potential of targeting C3 across a wide range of serious diseases.

With a foundation built on courageous science and compassion, Apellis strives to be recognized for their revolutionary science, compassion, and contributions to humankind worldwide. They value corporate responsibility and aim to bring transformative medicines to patients while providing an engaging and inclusive workplace for their employees. Apellis Pharmaceuticals is committed to their vision of improving lives through breakthrough treatments